Research programme: rhinovirus therapeutic - Alios BioPharmaAlternative Names: Rhinovirus nuc inhibitor
Latest Information Update: 10 Nov 2014
At a glance
- Originator Alios BioPharma
- Class Nucleosides
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Rhinovirus infections
Most Recent Events
- 07 Nov 2014 Alios BioPharma has been acquired by Johnson & Johnson
- 07 Apr 2014 Preclinical trials in Rhinovirus infections in USA (unspecified route)